R&D Sponsored 12 Questions with Faruk Uzman Find out more about Faruk Uzman, VP EMEA at Boston Scientific, in a new 12 Questions With.
R&D The conflict in the Middle East is exposing dangerous prepar... If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.
R&D LSX2026: Endogenous tissue restoration in vascular disease –... Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.
R&D Neuroplasticity modulators as innovative potential disease-m... In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome
R&D 3 big unanswered questions about psychedelics When it comes to psychedelics in the mental health space, there are still some important foundational questions lacking settled answers.
R&D Sponsored The future of cardiometabolic trials: From obesity to outcom... Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO
News ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
